Evidence map›Paper›PMID 38271158›Full record

Observational studyJapanese journal of clinical oncology2024

First-line nivolumab plus ipilimumab with or without chemotherapy for Japanese patients with non-small cell lung cancer: LIGHT-NING study.

Hisao Imai, Takashi Kijima, Koichi Azuma, Kazuma Kishi, Haruhiro Saito, Teppei Yamaguchi, Junko Tanizaki, Yasuto Yoneshima, Kohei Fujita, Satoshi Watanabe and 11 more

Erratum issuedOpen access · hybridAbstract readObservational StudyMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Japanese journal of clinical oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.5field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 9 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Observational
  5. Article
  6. Article
  7. Observational
  8. Observational
  9. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

21 authors at 18 institutions in 2 countries.

Hisao ImaiDepartment of Respiratory Medicine, Comprehensive Cancer Center, International Medical Center, Saitama Medical University, Saitama, Japan.ORCID 0000-0003-3097-4255
Takashi KijimaDepartment of Respiratory Medicine and Hematology, Hyogo Medical University, School of Medicine, Nishinomiya, Hyogo, Japan.
Koichi AzumaDivision of Respirology, Neurology and Rheumatology, Department of Internal Medicine, Kurume University, School of Medicine, Fukuoka, Japan.
Kazuma KishiDepartment of Respiratory Medicine, Toho University Omori Medical Center, Tokyo, Japan.
Haruhiro SaitoDepartment of Thoracic Oncology, Kanagawa Cancer Center, Kanagawa, Japan.
Teppei YamaguchiDepartment of Thoracic Oncology, Aichi Cancer Center Hospital, Aichi, Japan.ORCID 0000-0002-8909-5709
Junko TanizakiDepartment of Medical Oncology, Kindai University Faculty of Medicine, Osaka, Japan.ORCID 0000-0002-6727-9435
Yasuto YoneshimaDepartment of Respiratory Medicine, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Kohei FujitaDivision of Respiratory Medicine, National Hospital Organization Kyoto Medical Center, Kyoto, Japan.
Satoshi WatanabeDepartment of Respiratory Medicine and Infectious Diseases, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.
Satoru KitazonoDepartment of Thoracic Medical Oncology, the Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.
Tatsuro FukuharaDepartment of Respiratory Medicine, Miyagi Cancer Center, Miyagi, Japan.
Osamu HatajiRespiratory Center, Matsusaka Municipal Hospital, Mie, Japan.
Yukihiro ToiDepartment of Pulmonary Medicine, Sendai Kousei Hospital, Miyagi, Japan.
Hideaki MizutaniDepartment of Thoracic Oncology, Saitama Cancer Center, Saitama, Japan.
Yusuke HamakawaDepartment of Respiratory Medicine, Yokohama Municipal Citizen's Hospital, Kanagawa, Japan.
Makoto MaemondoDivision of Pulmonary Medicine, Department of Internal Medicine, Iwate Medical University School of Medicine, Iwate, Japan.
Tomoyuki OhsugiOncology Medical, Bristol Myers Squibb, Tokyo, Japan.
Keisuke SuzukiOncology Medical Affairs, Ono Pharmaceutical Co, Ltd, Osaka, Japan.
Hidehito HorinouchiDepartment of Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan.ORCID 0000-0001-9090-801X
Yuichiro OheDepartment of Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan.ORCID 0000-0002-6137-073X
Aichi Cancer Center · JPBristol-Myers Squibb (Japan) · JPIwate Medical University · JPJapanese Foundation For Cancer Research · JPKanagawa Prefectural Hospital Organization · JPKindai University · JPKurume University · JPKyoto Medical Center · JPKyushu University · JPMiyagi Prefectural Hospital Organization · JPNiigata University · JPOno Pharmaceutical (Japan) · JPSaitama Cancer Center · JPSaitama International Medical Center · JPSendai Kousei Hospital · JPSoka Municipal Hospital · JPToho University · JPYokohama Municipal Citizen's Hospital · JP

Funding

Bristol Myers Squibb, Tokyo, JapanOno Pharmaceutical Co, Ltd, Osaka, Japan
6 · The paper itself

Abstract

objectiveAs first-line treatment for stage IV or recurrent non-small cell lung cancer, combination immunotherapy with nivolumab and ipilimumab, with or without chemotherapy, had demonstrated survival benefits over chemotherapy; however, data on Japanese patients are limited.

methodsLIGHT-NING was a multicenter, observational study and retrospectively collected data. In this interim analysis, we analyzed patients who received combination immunotherapy between 27 November 2020 and 31 August 2021 for the treatment status, safety objectives (treatment-related adverse events and immune-related adverse events incidences), and effectiveness objectives (objective response rate and progression-free survival) to determine the characteristics and early safety information.

resultsWe analyzed 353 patients, with a median follow-up of 7.1 (interquartile range, 5.0-9.7) months. Overall, 60.1 and 39.9% received nivolumab plus ipilimumab with and without chemotherapy, respectively. In these cohorts, the median age was 67 and 72 years; 10.8 and 35.5% were aged ≥75 years; 80.2 and 79.4% were male; 5.2 and 13.5% had a performance score ≥ 2; 32.1 and 27.0% developed grade 3-4 immune-related adverse events; treatment-related deaths were observed in 6 (2.8%) and 5 (3.5%) patients, respectively. Grade 3-4 immune-related adverse event incidence was the highest within the first month of treatment in both cohorts, although the immune-related adverse event risk persisted throughout. No new safety signals were observed at this interim analysis. The median progression-free survival was 6.0 (95% confidence interval, 5.2-7.6) and 5.8 (4.3-7.0) months in nivolumab plus ipilimumab with and without chemotherapy cohorts, respectively.

conclusionsLIGHT-NING offers valuable insights into combination immunotherapy for untreated patients with stage IV or recurrent non-small cell lung cancer in Japanese real-world settings.

Indexed as

Carcinoma, Non-Small-Cell LungLung NeoplasmsAgedAntineoplastic Combined Chemotherapy ProtocolsFemaleHumansIpilimumabJapanMaleNeoplasm Recurrence, LocalNivolumabRetrospective StudiesIpilimumabNivolumabipilimumabJapannivolumabnon-small-cell lung carcinomaobservational study

Identifiers

PMID38271158
PMCPMC10999773
OpenAlexW4391231245

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.